DISCOUNT ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 14:08:20 2024-06-05 EDT | ||
| 225 EUR | +0.23% |
|
| Current month | +0.18% | ||
| 1 month | +0.20% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-05 | 225 | +0.23% |
| 24-06-04 | 224.5 | +0.14% |
| 24-06-03 | 224.2 | -0.18% |
| 24-05-31 | 224.6 | +0.04% |
| 24-05-30 | 224.5 | -0.24% |
Delayed Quote Börse Stuttgart
Last update June 05, 2024 at 02:08 pm
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MG1BSY |
| ISIN | DE000MG1BSY5 |
| Date issued | 2024-04-02 |
| Maturity | 2025-03-21 (289 Days) |
| Parity | 1 : 1 |
| Emission price | 222.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 226.2 € |
|---|---|
| Lowest since issue | 220.4 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483
USD
Average target price
463.5
USD
Spread / Average Target
-4.04%
- Stock Market
- Certificates
- Certificat
